Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth Woods

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 23, 2011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesotheliomaBeth Woods, Noman Paracha, David A Scott, et al.
BMC Medical Research Methodology|May 23, 2021
Classifying information-sharing methodsGeorgios F Nikolaidis, Beth Woods, Stephen Palmer, et al.
Health Economics|January 16, 2024
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments requiredBeth Woods, James Lomas, Mark Sculpher, et al.
Journal of Medical Economics|December 7, 2013
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and WalesSarah Dewilde, Beth Woods, Jean-Gabriel Castaigne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysisBeth Woods, Neil Hawkins, William Dunlop, et al.
Lancet (London, England)|December 15, 2024
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysisHuseyin Naci, Peter Murphy, Beth Woods, et al.
BMJ Global Health|December 14, 2021
Concomitant health benefits package design and research prioritisation: development of a new approach and an application to MalawiLaetitia Schmitt, Jessica Ochalek, Karl Claxton, et al.
Research Synthesis Methods|February 2, 2026
Methods for information-sharing in network meta-analysis: Implications for inference and policyGeorgios F Nikolaidis, Beth Woods, Stephen Palmer, et al.
Lancet (London, England)|June 28, 2025
Population health impact of NICE-recommended new drugs - Authors' replyHuseyin Naci, Peter Murphy, Beth Woods, et al.
Applied Health Economics and Health Policy|May 9, 2025
Antimicrobial Resistance (AMR) Development Map: A Conceptual Map and a Tool to Support Economic Evaluation of AMR InterventionsKristina Aluzaite, Marta O Soares, Catherine Hewitt, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|September 23, 2011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesotheliomaBeth Woods, Noman Paracha, David A Scott, et al.
BMC Medical Research Methodology|May 23, 2021
Classifying information-sharing methodsGeorgios F Nikolaidis, Beth Woods, Stephen Palmer, et al.
Health Economics|January 16, 2024
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments requiredBeth Woods, James Lomas, Mark Sculpher, et al.
Journal of Medical Economics|December 7, 2013
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and WalesSarah Dewilde, Beth Woods, Jean-Gabriel Castaigne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysisBeth Woods, Neil Hawkins, William Dunlop, et al.
Lancet (London, England)|December 15, 2024
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysisHuseyin Naci, Peter Murphy, Beth Woods, et al.
BMJ Global Health|December 14, 2021
Concomitant health benefits package design and research prioritisation: development of a new approach and an application to MalawiLaetitia Schmitt, Jessica Ochalek, Karl Claxton, et al.
Research Synthesis Methods|February 2, 2026
Methods for information-sharing in network meta-analysis: Implications for inference and policyGeorgios F Nikolaidis, Beth Woods, Stephen Palmer, et al.
Lancet (London, England)|June 28, 2025
Population health impact of NICE-recommended new drugs - Authors' replyHuseyin Naci, Peter Murphy, Beth Woods, et al.
Applied Health Economics and Health Policy|May 9, 2025
Antimicrobial Resistance (AMR) Development Map: A Conceptual Map and a Tool to Support Economic Evaluation of AMR InterventionsKristina Aluzaite, Marta O Soares, Catherine Hewitt, et al.
Pageof 5